Rani Therapeutics Holdings, Inc. (RANI) AI Stock Analysis

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on drug delivery through its proprietary RaniPill capsule platform. The platform is designed to replace subcutaneous or IV injections by administering biologics orally. The company's pipeline includes RT-101, an octreotide in Phase I clinical trials for neuroendocrine tumors and acromegaly, and RT-105, an anti-TNF-alpha antibody targeting psoriatic arthritis. In preclinical development, Rani Therapeutics is advancing RT-102 for osteoporosis, RT-109 for growth hormone deficiency, RT-110 for hypoparathyroidism, and RT-106, a basal insulin for type 2 diabetes management. Headquartered in San Jose, California, the company was founded in 2012.

Rani Therapeutics generated revenue of $1.6M in FY2025, up 58.9% from $1.0M in FY2024, following $2.7M in FY2021. Gross margin was 44.9% in FY2025, down from 100.0% in FY2024. Operating margin was -2346.0% in FY2025, compared to -5186.2% in FY2024. Net income remained negative at -$29.7M in FY2025, with an EPS of -$0.59. Between FY2019 and FY2025, revenue expanded at a four-year compound annual growth rate of 13.6%. For the trailing twelve months ended June 30, 2026, revenue stood at $4.9M with quarterly revenue growth of 893.0% year-over-year, alongside an operating margin of -516.9% and an EPS of -$0.15.

As of June 30, 2026, Rani Therapeutics had $53.4M in cash and short-term investments and $3.5M in total debt, resulting in net cash of $49.8M. Total assets stood at $60.8M, shareholders' equity was $39.2M, and the current ratio was 5.31. Operating cash flow in FY2025 was -$18.7M, and free cash flow was -$18.8M. Capital expenditures were $88,000 in FY2025. Over the five-year period, the company's share count increased by 862.8%.

At a last close of $0.64 on October 16, 2026, Rani Therapeutics had a market cap of $90.0M and an enterprise value of $38.7M. The stock trades at a price-to-sales multiple of 18.5x, above the 4.1x median of its US-listed Healthcare peers, and an enterprise value-to-revenue ratio of 7.9x. Price-to-book stands at 2.3x. Over the past year, the stock returned 36.1%, outperforming the S&P 500 (SPY) return of 16.8%, but is down 52.5% year-to-date and 96.7% over five years versus an 83.0% five-year gain for SPY.

Wall Street analysts maintain 4 Strong Buy ratings and 1 Buy rating on Rani Therapeutics, with zero Hold, Sell, or Strong Sell ratings. The mean price target is $7.20, representing an upside of 1023.2% from the last close of $0.64. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $6.3M and an EPS of -$0.17. For the next fiscal year, 3 analysts forecast revenue of $6.6M and an EPS of -$0.19. Over the last four quarters, the company delivered 1 EPS beat. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Rani Therapeutics Holdings, Inc. (RANI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RANI income statement, RANI balance sheet, RANI key metrics, RANI analyst forecast, RANI chart. See the RANI stock overview for the latest quote and news.